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ABSTRACT Two mutations (K141E, K141N) in the
small heat shock protein (sHSP) HSP22 (HSPB8) are
associated with the inherited peripheral motor neuron
disorders distal hereditary motor neuropathy type II
and axonal Charcot-Marie-Tooth disease type 2L.
HSP22 is known to form homodimers, heterodimers
with other sHSPs, and larger oligomers. In an effort to
elucidate the cellular basis for these diseases, we have
determined the ability of mutant HSP22 to interact with
itself, with wild-type HSP22, and with other sHSPs that
are abundant in neurons. Using the yeast two-hybrid
method, quantitative fluorescence resonance energy
transfer in live cells, and cross-linking, we found aber-
rantly increased interactions of mutant HSP22 forms
with themselves, with wild-type HSP22, and with the
other sHSPs, B-crystallin, and HSP27. Interaction
with HSP20 was not affected by the mutations. The
data suggest that each mutant form of HSP22 has a
characteristic pattern of abnormal interaction proper-
ties. A mutation (S135F) in HSP27 that is also associ-
ated with these disorders showed increased interaction
with wild-type HSP22 also, suggesting linkage of these
two etiologic factors, HSP22 and HSP27, into one
common pathway. Increased interactions involving mu-
tant sHSPs may be the molecular basis for their in-
creased tendency to form cytoplasmic protein aggre-
gates, and for the occurrence of the associated
neuropathies.—Jean-Marc Fontaine, Xiankui Sun,
Adam D. Hoppe, Stephanie Simon, Patrick Vicart,
Michael J. Welsh, and Rainer Benndorf. Abnormal
small heat shock protein interactions involving neurop-
athy-associated HSP22 (HSPB8) mutants. FASEB J. 20,
E1579–E1588 (2006)
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Patients with the inherited peripheral neuropathies
distal hereditary motor neuropathy (dHMN) and ax-
onal Charcot-Marie-Tooth disease (CMT) suffer pro-
gressive weakness and atrophy of the muscles, initially
in the lower limbs and later also in the distal upper
limbs (1). Patients with CMT have, in addition to the
motor abnormalities, also sensory abnormalities. Cur-
rently, there is no cure for these disorders. Both
disorders are clinically and genetically heterogeneous,
and the number of identified genes that, when mu-
tated, cause these diseases has risen substantially in
recent years (2, 3). Among the affected genes is the
gene encoding the small heat shock protein (sHSP) 22
(HSP22, also known as HSPB8, H11; gene name:
HSPB8) (4, 5). So far, five families with dHMN type II
or CMT type 2L carrying mutations in the HSPB8 gene
have been identified (6, 7). The two mutations known
to date affect the “hot spot” amino acid residue Lys141
in the wild-type HSP22 (wtHSP22) protein sequence
changing it to either Glu (K141EHSP22) or Asn
(K141NHSP22). In affected individuals, both the wild-type
and mutant HSPB8 alleles are expressed, and both mu-
tants have dominant gain-of-function characteristics (6).
In mammals, several of the sHSPs such as HSP22,
HSP27, B-crystallin (B-Cry), and HSP20 are ex-
pressed in a variety of organs and tissues, including
neuronal tissues (8). sHSPs form dimers that are the
basic building blocks for higher molecular mass oligo-
meric structures or complexes (9, 10). In addition to
homodimers, sHSPs can form heterodimers and mixed
heterooligomers, although not all possible sHSP inter-
actions may occur in cells (11, 12). Most cells contain
sHSP species ranging from dimers to approximately
quadragintamers. This mixed complex formation is a
prominent, although not well understood, property of
sHSPs. HSP22 has been shown to form homodimers
and also heterodimers with HSP27, B-Cry, HSP20, and
other sHSPs (12, 13). Recently, a number of mutations
in HSP27 (muHSP27) and B-Cry has been identified
that are also associated with neuropathies and with
myopathies. These mutations include R127WHSP27,
S135FHSP27, R136WHSP27, T151IHSP27, P182LHSP27, and
P182SHSP27 (all associated with dHMN and/or CMT),
R120GB-Cry, 464CTB-Cry, and Q151XB-Cry (all associ-
ated with desmin-related or myofibrillar myopathy),
and R157HB-Cry (associated with dilated cardiomyopa-
thy) (14–19).
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A hallmark of many neurodegenerative diseases,
including Parkinson, Alzheimer, and Alexander dis-
eases, is the misfolding and precipitation of proteins in
the nervous system referred to as aggresome or amyloid
formation (20). Each such amyloid disease usually
involves the aggregation of a specific protein, with a
range of other proteins being also incorporated into
the aggregates. sHSPs are found in at least one type of
these aggregates together with intermediate filament
proteins (21). As far as studied, the neuropathy- and
myopathy-associated mutant forms of HSP22, HSP27,
and B-Cry also form aggregates, which is thought to
contribute to the manifestation of the associated dis-
eases (6, 14, 22, 23).
Using the yeast two-hybrid (TH) method, chemical
cross-linking (CL), and quantitative fluorescence reso-
nance energy transfer (qFRET) in live mammalian
cells, we show herein that both mutant HSP22
(muHSP22) proteins are capable of interacting with
themselves, with wtHSP22, and with other sHSPs, and
that the muHSP22 proteins have abnormally increased,
although different, interaction properties. Similarly,
disease-associated S135FHSP27 has an increased interac-
tion with wtHSP22 as compared with wild-type HSP27
(wtHSP27), thus providing a rationale for the observa-
tion that mutations in both, HSP22 (K141EHSP22,
K141NHSP22) and HSP27 (S135FHSP27) result in similar
disease phenotypes.
It is hypothesized that these abnormal sHSP interac-
tions are the molecular basis for both the formation of
cytoplasmic protein aggregates and eventually for the
development of the associated disorders dHMN type II
and CMT type 2.
MATERIALS AND METHODS
Vector constructs
TH vector constructs were made using the vectors pGBKT7,
pGADT7, and pACT2 (BD Biosciences, San Jose, CA). Cyan
(CFP) and citrine (CIT) fluorescent sHSP fusion protein
expression vectors were made using the vectors peCFPN1 (BD
Biosciences) and peCITN1 (24). myc-HSP22 constructs were
made using the vectors pcDNA3.1-myc (Invitrogen, Carlsbad,
CA). The mutant forms of HSP22 were made by site-directed
mutagenesis using the QuickChangeXL kit (Stratagene, La
Jolla, CA). More detailed cloning information is given in
Table 1 and in previous publications (12, 13, 25).
Two-hybrid method
Small-scale sequential transformation of the yeast strain
AH109 was performed as described in the manufacturer’s
instructions (BD Biosciences). The yeast was first transformed
with constructs pGBKT7-wtHSP22 [13] (the underlined num-
bers in brackets designate the used vector constructs as
specified in Table 1), pGBKT7-K141EHSP22 [15], or pGBKT7-
K141NHSP22 [17], and grown on –Trp medium as described
previously (13). In the second step, the yeast were trans-
formed with the complementary vectors, as specified in Figs.
2A, 5A, and 7A. Selection was on -Trp,-Leu,-His medium for
the phenotype His (growth). Additionally, the colonies
were analyzed for the phenotype LacZ (blue color) using
the colony filter lift assay. The interaction assays were consid-
ered positive only if both reporter genes were activated. For
the negative TH controls, yeasts were transformed with each
vector alone and tested on -Trp/-Leu/-His medium (not
shown). Additionally, yeasts were cotransformed with each
vector and with the “empty” partner vector (controls C1–C14
in Figs. 2B, 5B, 7B). In none of these controls were the
reporter genes activated.
Live cell imaging and quantitative fluorescence resonance
energy transfer (qFRET)
CFP- and CIT-sHSP fusion protein expression vectors were
used for these experiments. CIT is a variant of the yellow
fluorescent protein (YFP) that is superior for qFRET (24).
COS-7 cells were grown in glass-bottom six-well culture plates
(MatTek Corporation, Ashland, MA) in Dulbecco’s modified
Eagle medium (DMEM) (Life Technologies, Inc., Carlsbad,
CA) supplemented with 10% fetal calf serum (Invitrogen) in
a 5% CO2 humidified atmosphere at 37°C. Cells were trans-
fected at 60% confluency with 0.75 g (single construct) or
1.5 g (two constructs) vector DNA using FuGene6 (Roche
Applied Science, Indianapolis, IN). Twenty-four h later, the
live cells that express the CFP- and CIT-sHSP fusion proteins
were washed 2 times with PBS and kept in DMEM medium
without phenol red (Invitrogen) for collecting the fluores-
cence images at 37°C.
For fluorescence imaging, an inverted epifluorescence
microscope (Eclipse TE-2000 U; Nikon, Melville, NY)
equipped with a 100 W Mercury Arc-lamp, exciter filters
430/25 and 500/20, a dichroic microscope filter 86002bs,
and with a 505dcxr Dual View Micro Imager MSMI.DV.CC
(Optical Insights, Tucson, AZ) with the emission filters
470/30 and 535/30, was used. Images were collected by a
digital CoolSnap CCD camera (Photometrics, Huntington
Beach, CA) and using Metamorph image processing software
version 6.2r5 (Molecular Devices, Sunnyvale, CA).
HSP22-CIT fusion proteins (both wild-type and mutants)
expressed in COS-7 cells formed aggregates. The proportion
of cells with aggregates was determined 24 h after transfec-
tion. For counting, randomly selected microscopic fields were
evaluated using a Plan fluor ELWD 40x/0.6 objective lens
(Nikon).
We applied the qFRET method to quantify apparent fluo-
rescence resonance energy transfer efficiencies as indicators
of protein interactions (24, 26). The configuration of the
microscope was as described above, with the exception that a
Fluor ELWD 40x/1.3 oil Dic H objective lens (Nikon) was
used. IA, ID, and IF images from at least 30 microscopic fields
per sample group were acquired and background/shading-
corrected prior to computation by the qFRET algorithm. The
apparent FRET efficiencies EA and ED were determined (EA,
apparent acceptor efficiency calculated from sensitized emis-
sion and dependent on the fraction of acceptor in complex;
ED, apparent donor efficiency calculated relative to donor
fluorescence and dependent on the fraction of the donor in
complex). EA and ED are proportional to the fraction of the
interaction partners in complex. The calculated output data
were expressed as the apparent average fluorescence reso-
nance energy transfer efficiency, or AAFE ([EA  ED]/2).
Only cells without protein aggregates were included in this
analysis. As negative control, the cells were transfected with
the “empty” CFP (peCFPN1) and CIT (peCITN1) vectors.
Expression of the corresponding fluorescent proteins re-
sulted in a minor interaction signal that defined the baseline
level. AAFE values that were significantly different from that
signal indicated interaction.
E1580 Vol. 20 October 2006 FONTAINE ET AL.The FASEB Journal
Toxicity assay
COS-7 cells were transfected with wtHSP22-CIT [4], K141EHSP22-
CIT [6], and K141NHSP22-CIT [8], or transfected with the
“empty” CIT vector for control. Toxicity of the various
HSP22-CFP species was evaluated after 24 h by determining
the percentage of dead cells in each sample group using the
Live/Dead Viability/Cytotoxicity kit (Invitrogen).
Cross-linking
HEK-293T cells were grown at 37°C in poly-l-lysine-pretreated
6-well plates in DMEM medium supplemented with 10% fetal
calf serum in a 5% CO2 humidified atmosphere. Cells were
transfected at 80% confluency with 2 g of vector DNA of
myc-tagged HSP22 species [1, 2, 3] using Lipofectamine 2000
(Invitrogen). 48 h later, cells were collected and washed three
times with ice-cold PBS (pH 8.0). Cells were incubated with
either 0.5 or 5 mM of the homobifunctional amine-reactive
cross-linker disuccinimidyl suberate (DSS; Pierce, Rockford,
IL) for 30 min at room temperature. The reaction was
stopped by adding Tris-HCl (pH 7.5) to 15 mM final concen-
tration. Fifteen minutes later, 1 vol of sample buffer (125 mM
Tris-HCl, pH 6.8; 4% SDS; 20% glycerol; 400 mM dithiothre-
itol; 0.01% bromphenol blue) was added. After a brief
sonication and boiling for 5 min, the samples were analyzed
by SDS-PAGE and Western blot analysis. A monoclonal anti-
myc primary antibody (Ab) (Sigma, St. Louis, MO) and a goat
antimouse horseradish-coupled secondary Ab (Pierce) were
used for immunodetection.
Data and statistics
Quantitative data are expressed as mean  se. Unpaired
Student’s t test was applied to compare results between
sample groups. The number of counted cells for each value
was at least 400 in Fig. 1E (4n7), and 300 in the viability
assay (11n13). The number of cells analyzed by the
qFRET method were at least 47 in Figs. 3B, 6B, 7D (n47).
Differences between groups were considered statistically sig-
nificant if P  0.05.
RESULTS
Intracellular localization of muHSP22 and formation
of protein aggregates
After transfection of mammalian cells with aggregate-
forming proteins, these structures form in the cyto-
plasm in a time-dependent process usually starting at
multiple foci. These multifoci type aggregates are then
transported along microtubules to finally form a peri-
centrosomal mass (27, 28). Coexpression of aggregate-
TABLE 1. Designation of the constructs, origin of the sHSP cDNA, and cloning methods
Construct Construct Designation Method of Cloning/Source of sHSP cDNA
Restriction
Sites Used Primersa
Number
1 pcDNAmyc-wtHSP22 described previouslyb — —
2 pcDNAmyc-K141EHSP22 site-directed mutagenesis of construct 1 — 1, 2
3 pcDNAmyc-K141NHSP22 site-directed mutagenesis of construct 1 — 3, 4
4 peCITN1-wtHSP22 PCR of construct 1, TopoTA cloning EcoRI, KpnI 5, 6
5 peCFPN1-wtHSP22 PCR of construct 1, TopoTA cloning EcoRI, KpnI 5, 6
6 peCITN1-K141EHSP22 PCR of construct 2, TopoTA cloning EcoRI, KpnI 5, 6
7 peCFPN1-K141EHSP22 PCR of construct 2, TopoTA cloning EcoRI, KpnI 5, 6
8 peCITN1-K141NHSP22 PCR of construct 3, TopoTA cloning EcoRI, KpnI 5, 6
9 peCFPN1-K141NHSP22 PCR on construct 3, TopoTA cloning EcoRI, KpnI 5, 6
10 peCFPN1-HSP20 PCR of pAS2–1-HSP20C,D, TopoTA cloning EcoRI, KpnI 7, 8
11 peCFPN1- B-Cry described previouslyc
12 peCFPN1-wtHSP27 described previouslyb — —
13 pGBKT7-wtHSP22 subcloning of pACT2-wtHSP22b NdeI, EcoRI —
14 pGADT7-wtHSP22 subcloning of pACT2-wtHSP22b NdeI, EcoRI —
15 pGBKT7-K141EHSP22 site-directed mutagenesis of construct 13 — 1, 2
16 pGADT7-K141EHSP22 site-directed mutagenesis of construct 14 — 1, 2
17 pGBKT7-K141NHSP22 site-directed mutagenesis of construct 13 — 3, 4
18 pGADT7-K141NHSP22 site-directed mutagenesis of construct 14 — 3, 4
19 pACT2-wtHSP27(a)e described previouslyd — —
20 pACT2-HSP20e described previouslyd — —
21 pACT2- B-Crye described previouslyc — —
22 pACT2-wtHSP27(b)e PCR of construct 19 EcoRI, XhoI 9, 10
23 pACT2-S135FHSP27e site-directed mutagenesis of construct 22 — 11, 12
24 peCITN1-wtHSP27 PCR of construct 12 EcoRI, HindIII 13, 14
25 peCITN1-S135FHSP27 site-directed mutagenesis of construct 24 — 11, 12
a For each primer pair, the first and second numbers refer to the forward and reverse primers, respectively. Primers: 1, 5-
ctaagaacttcacagagaaaatccagcttcctgc; 2, 5-gcaggaagctggattttctctgtgaagttcttag; 5-gtttctaagaacttcacaaacaaaatccagcttcctgcagagg; 4, 5-cctctgcag-
gaagctggattttgtttgtgaagttcttagaaac; 5, 5-agaacttcacaaacaaaatccagct; 6, 5’-agctggattttgtttgtgaagttct; 5, 5-ccggaattcagtgtggtggaattcaac; 6, 5-cgggg-
tacccaggtacaggtgacttcc; 7, 5-ccggaattcatggagatccctgtgcctg; 8, 5-cggggtacccacttggctgcggctggcg; 9, 5-aaaaaagaattcgaatgaccgagcgcc; 10, 5-
aaaaaactcgagctcacttggcggcag; 11, 5-atggctacatcttccggtgcttcacg; 12, 5-tgaagcaccggaagatgtagccatgc; 13, 5-aaaaaaaagcttatgaccgagcgccgc; 14,
5-aaaaagaattcgcacttggcggcagt. b Sun et al., 2004 (13). c Fontaine et al., 2005 (12). d Sun et al., 2006 (25). e pACT2 is compatible
with pGBKT7 in TH assays
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forming mutant sHSPs with wild-type sHSPs can atten-
uate this aggregate formation (29). To estimate the
aggregate-forming potency of the used muHSP22-CIT
fusion proteins, and to relate it to the interaction data
(see below), we determined the proportion of aggre-
gate-containing cells when muHSP22 was expressed
alone or together with wtHSP22, HSP20, B-Cry, or
wtHSP27 as CFP fusion proteins.
In control experiments CIT and CFP alone did not
form aggregates when expressed in COS-7 cells. Repre-
sentative cells with nearly even cytoplasmic distribution
of CIT and CFP are shown in Fig. 1A. Similarly, the
expression of any of the used constructs of HSP20-CFP
[10], B-Cry-CFP [11], and wtHSP27-CFP [12] alone
did not result in any significant aggregate formation
(not shown). In contrast, 24 h after transfection,
wtHSP22-CIT [4], K141EHSP22-CIT [6], or K141NHSP22-
CIT [8] resulted in the formation of cytoplasmic mul-
tifoci type aggregates (Fig. 1B), although with a differ-
ent incidence (see below). Coexpression of both forms
of muHSP22-CIT [6, 8] with wtHSP22-CFP [5] resulted
in colocalization in the aggregates (Fig. 1C), while at
the same time, the proportion of cells containing
aggregates was decreased (see below). Similarly, coex-
pression of both muHSP22-CIT forms [6, 8] and of
wtHSP22-CIT [4] with HSP20-CFP [10], B-Cry-CFP [11],
and wtHSP27-CFP [12] resulted in recruitment of these
sHSPs into aggregates (Fig. 1D), as well as again lessen-
ing the proportion of cells containing aggregates (see
below).
To quantify both the tendency of the muHSP22
proteins to form aggregates and the ability of wild-type
sHSPs to attenuate aggregate formation, the propor-
tion of cells containing aggregates after transfection
was calculated in these experiments. Expression of
wtHSP22-CIT [4] resulted in aggregate formation in
17% of cells. This defined the baseline level for this
construct in COS-7 cells (Fig. 1E, control group).
Expression of K141EHSP22-CIT [6] and K141NHSP22-CIT
[8] resulted in a slightly and greatly increased aggre-
gate formation affecting 21% and 54%, respectively,
of the transfected cells. Thus, both muHSP22 proteins
have increased propensities to form aggregates, al-
though to a different extent. Coexpression of wtHSP22-
CFP [5] with K141EHSP22-CIT [6] or with K141NHSP22-
CIT [8] significantly decreased aggregate formation to
15% and 37% (Fig. 1E, HSP22 group), respectively, as
compared to expression of muHSP22 alone (Fig. 1E,
control group).
To determine the effect of other sHSPs (HSP20,
B-Cry, wtHSP27) on aggregate formation of wtHSP22
and muHSP22, similar coexpression experiments were
performed. In general, coexpression of HSP20-CFP [10],
B-Cry-CFP [11], and wtHSP27-CFP [12] attenuated the
formation of aggregates that was caused by expression
Figure 1. Aggregate formation of wtHSP22 and disease-associ-
ated muHSP22 in COS-7 cells. A) Representative images of
control cells expressing CIT or CFP alone. B) Representative
images of aggregate-containing cells expressing wtHSP22-CIT
[4], K141EHSP22-CIT [6], or K141NHSP22-CIT [8] alone. C)
Representative images of aggregate-containing cells coex-
pressing K141EHSP22-CIT/wtHSP22-CFP [6/5] or K141NHSP22-
CIT/wtHSP22-CFP [8/5]. D) Selected images of aggregate-con-
taining cells coexpressing wtHSP22-CIT [4], K141EHSP22-CIT
[6], or K141NHSP22-CIT [8] with HSP20-CFP [10], B-Cry-
CFP [11], or HSP27-CFP [12]. Only the CFP images are
shown. E) Proportion of cells with aggregates 24 h after
transfection. The usage of vectors was as in B–D. wtHSP22,
K141EHSP22, or K141NHSP22 were transfected alone (control
group), or cotransfected with HSP20-CFP (HSP20 group),
B-Cry-CFP (B-Cry group), or HSP27-CFP (HSP27 group).
K141EHSP22 and K141NHSP22 were also cotransfected with
wtHSP22 (HSP22 group). Significant differences within each
group (, muHSP22 vs. wtHSP22; , K141NHSP22 vs.
K141EHSP22) and to the corresponding values of the control
group (	) are indicated. The bar in A indicates 50 m.
Abbreviations: wt, wtHSP22; E, K141EHSP22; N, K141NHSP22.
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of either wtHSP22-CIT [4], K141EHSP22-CIT [6], or
K141NHSP22-CIT [8](Fig. 1E; HSP20, B-Cry, and
HSP27 groups), as compared to the expression of the
corresponding HSP22 species alone (Fig. 1E; control
group). However, the obtained patterns were different
for each of the tested sHSPs. For example, aggregate
formation by K141NHSP22-CIT was more effectively at-
tenuated by HSP20 or B-Cry than by wtHSP27, whereas
aggregate formation by wtHSP22-CIT was most effec-
tively attenuated by B-Cry or wtHSP27.
It has been reported that ectopic expression of both
forms of muHSP22 in N2a neuronal cells reduced cell
viability significantly 48 h after transfection (6). Aggre-
gate formation frequently correlates with reduced cell
viability and disease, although mature aggregates may
be relatively benign or even protective as compared to
early prefibrillar aggregates (20). In the context of our
study, reduced cell viability due to the possible toxicity
of the various HSP22 species could interfere with the
data presented in Fig. 1E. For that reason we evaluated
the toxicity of wtHSP22-CIT [4] and muHSP22-CIT [6,
8] constructs by determining the proportion of dead
cells using the Live/Dead Viability/Cytotoxicity kit.
Twenty four hours after transfection with wtHSP22-CIT,
K141EHSP22-CIT, or K141NHSP22-CIT, the proportion of
dead cells (se) was 3.27%  0.52, 4.44%  0.65, or
3.31  0.40, respectively, as compared with 3.08% 
0.57 dead cells in control cells transfected with the
“empty” CIT vector (all differences were statistically not
significant). Thus, none of the constructs caused a
significant decrease in the viability of the COS-7 cells
24 h after transfection.
Collectively, these data indicate that both muHSP22
proteins have an increased tendency to form aggre-
gates, and wild-type sHSPs can attenuate this aggregate
formation. Both muHSP22 proteins differ in their ag-
gregate formation tendency and in their responsiveness
to attenuation by wtHSP22 and other wild-type sHSPs,
thus indicating different properties between the two
muHSP22 forms.
Additionally, these data demonstrate that in all set-
tings, a significant proportion of cells is not affected by
aggregate formation 24 h after transfection. In these
cells, the sHSPs show a relatively even distribution in
the cytoplasm (cf. Figs. 3A, 6A, 7C). Such cells were
selected for qFRET measurements as described below.
Interactions of muHSP22 with itself and with wtHSP22
We have determined the ability of both muHSP22 forms to
interact with themselves and with wtHSP22. The wtHSP22/
wtHSP22 interaction was established previously and served
as a control (13). The TH experiments indicated
activation of both reporter genes in the interactions
K141EHSP22/wtHSP22 [16/13] and K141NHSP22/wtHSP22
[18/13](Fig. 2A). Similarly, the reporter genes were
activated in the interactions K141EHSP22/K141EHSP22
[15/16] and K141NHSP22/K141NHSP22 [17/18]. Thus,
all HSP22 species interacted with one another. Within
the limits of this method, no differences in the inter-
action intensities were observed as compared to the
wtHSP22/wtHSP22 [13/14] control interaction. All neg-
ative TH controls (C1–C6) were negative, thus render-
ing false-positive results unlikely (Fig. 2B).
For the qFRET analysis, COS-7 cells were transfected
with various vector pairs to be analyzed. Twenty-four
hours later, cells without aggregates and with even
cytoplasmic distribution of the expressed proteins were
selected. Representative cell images for all analyzed
HSP22 pairs are shown in Fig. 3A. The AAFE values
obtained for all tested interactions were significantly
different from the negative control, thus indicating
interaction (Fig. 3B). The AAFE for the K141EHSP22/
wtHSP22 [7/4] interaction was similar to that of the
wtHSP22/wtHSP22 [4/5] interaction, while the AAFE
for the K141EHSP22/K141EHSP22 [6/7] interaction was
moderately, though significantly, increased as com-
pared to that of the wtHSP22/wtHSP22 [4/5] interac-
tion. In contrast, K141NHSP22 [9] showed a strongly
(approximately two-fold) increased AAFE in the inter-
actions with both wtHSP22 [4] and with itself [8], as
compared to the wtHSP22/wtHSP22 [4/5] interaction.
We used cross-linking (CL) as another approach to
determine homodimer formation of the various HSP22
species. Additionally, this method can provide informa-
tion on the formation of oligomers larger than dimers.
HEK-293T cells were transfected with vectors to ex-
press myc-tagged wtHSP22 [1], K141EHSP22 [2], or
K141NHSP22 [3]. Forty-eight hours later, cells were
harvested, washed with PBS, and treated with 0.5 mM or
5 mM DSS, a homobifunctional cross-linker. The cross-
linked proteins were then processed for SDS-PAGE,
and Western blot analysis was performed using a myc-
specific Ab detection system (Fig. 4). CL of wtHSP22,
Figure 2. TH assays of the interactions of muHSP22 with
wtHSP22 and with themselves. A) Assays to determine the
interactions of K141EHSP22 [15] with wtHSP22 [14] and with
itself [16], and of K141NHSP22 [17] with wtHSP22 [14] and
with itself [18]. The wtHSP22/wtHSP22 [13/14] interaction
served as positive control. B) Negative TH controls: C1, C2,
C3, pGADT7 with wtHSP22 [13], K141EHSP22 [15], or
K141NHSP22 [17], respectively; C4, C5, C6, pGBKT7 with
wtHSP22 [14], K141EHSP22 [16], or K141NHSP22 [18], respec-
tively. Reporter genes: His (growth), LacZ (blue color).
Abbreviations are as in Fig. 1.
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K141EHSP22, or K141NHSP22 with 0.5 mM or 5 mM DSS
provided one major band each in the dimer region. CL
with 5 mM DSS resulted in additional bands at the
position of possibly tetramers, similar to earlier obser-
vations (13). No major differences in the intensities of
the bands between wtHSP22 and muHSP22 were ob-
served. The controls were 1) nontransfected and non-
cross-linked cells; 2) nontransfected and cross-linked
cells (0.5 and 5 mM DSS); and 3) transfected (wtHSP22,
K141EHSP22, K141NHSP22) and noncross-linked cells, as
indicated. Only in transfected cells was myc-HSP22
detected (either as monomers, dimers, or tetramers).
No dimer or tetramer bands of myc-HSP22 were de-
tected in any of the control cells. The endogenous myc
protein was detected in all cells (position indicated)
and did not interfere with the assays.
Collectively, the TH, qFRET, and CL data suggest
that the muHSP22 proteins interact with themselves and
with wtHSP22. Differences between wtHSP22 and both
muHSP22 forms could be demonstrated by the qFRET
method due to its greater sensitivity. At the dimer level,
K141NHSP22 had an increased interaction with wtHSP22,
and both muHSP22 proteins demonstrated increased
interaction with themselves, as compared to wtHSP22
interacting with itself. The interaction properties of
K141NHSP22 were more deviating from wtHSP22 than
those of K141EHSP22. The CL data suggest that both
muHSP22 forms had an ability similar to wtHSP22 to
form homotetramers.
Interactions of muHSP22 with HSP20, B-Cry,
and wtHSP27
Previously it was shown that wtHSP22 interacts with
HSP20, B-Cry, and wtHSP27 (12, 13). To determine
potentially abnormal interaction properties with these
sHSPs, both muHSP22 forms were probed in TH and
qFRET assays.
The TH data suggested that both K141EHSP22 [15]
and K141NHSP22 [17] interact with HSP20 [20], B-Cry
[21], and wtHSP27 [19], in a manner similar to wtHSP22
[13] (Fig. 5A). Within the limits of this method, no
differences in the interaction stoichiometry between
muHSP22 and wtHSP22 were observed. All negative TH
controls (C7–C12) provided negative results, as ex-
pected (Fig. 5B).
The qFRET analysis in doubly transfected cells was
performed as described above. In contrast to HSP22-
CIT fusion proteins, which are located in both the
cytoplasm and the nuclei, the fusion proteins HSP20-
CFP, B-Cry-CFP, and wtHSP27-CFP were largely ex-
cluded from nuclei. Representative CFP images of cells
coexpressing these three sHSP-CFP fusion proteins
together with the various forms of HSP22 are shown in
Fig. 6A. The AAFE values for K141EHSP22 [6] or
K141NHSP22 [8] with HSP20 [10] as interacting partner
were not significantly different from that of wtHSP22
[4], suggesting that the mutations do not affect this
interaction (Fig. 6B, HSP20 group). In contrast, the
AAFE values for K141EHSP22 [6] or K141NHSP22 [8]
with B-Cry [11] as interacting partner were moder-
ately, although significantly, increased (B-Cry group)
as compared with wtHSP22 [4], suggesting that this
Figure 3. qFRET measurements of the interactions of
muHSP22 forms with wtHSP22 and with themselves. A) Repre-
sentative images of doubly transfected COS-7 cells without
aggregates coexpressing wtHSP22/wtHSP22 [4/5], wtHSP22/
K141EHSP22 [4/7], wtHSP22/K141NHSP22 [4/9], K141EHSP22/
K141EHSP22 [6/7], or K141NHSP22/K141NHSP22 [8/9] as CIT
and CFP fusion proteins as indicated. The bar indicates 50
m. B) AAFE as determined by the qFRET method in doubly
transfected COS-7 cells expressing the various HSP22 species,
as indicated. The measured interactions, and the constructs
used were as in A. All sample values were significantly
different from the control. Significant differences from the
wtHSP22/wtHSP22 interaction (), from the wtHSP22/
K141EHSP22 interaction (), and from the K141EHSP22/
K141EHSP22 interaction (	) are indicated where appropri-
ate. Abbreviations: C, control; other abbreviations are as in
Fig. 1.
Figure 4. CL of wtHSP22 and muHSP22 in HEK-
293T cells. Cells were transfected with myc-tagged
wtHSP22 [1], K141EHSP22 [2], or K141NHSP22 [3]
cDNAs, or were not transfected, as indicated.
Forty-eight hours later, cell proteins were cross-
linked with 0.5 mM or 5 mM DSS, or were left
untreated. After CL, cells were harvested and
processed for SDS-PAGE/Western blot analysis
using a myc-specific Ab. Scale on the left: posi-
tions of molecular mass marker proteins. Scale on
the right: positions of HSP22 monomers (1),
HSP22 dimers (2), possibly HSP22 tetramers (4),
and of the endogenous myc protein (myc).
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interaction is affected by both mutations. The AAFE
values for both muHSP22 proteins were similar when
compared to each other. Finally, the AAFE values for
K141EHSP22 [6] and K141NHSP22 [8] were moderately
and strongly, respectively, increased with wtHSP27 [12]
as interacting partner (HSP27 group), as compared
with wtHSP22 [4]. Thus, both mutations result in in-
creased interaction with wtHSP27, although to a differ-
ent extent.
Taken together, these data suggest that both
muHSP22 proteins interact with HSP20, B-Cry, and
wtHSP27. Additionally, the data reveal increased in-
teractions of both muHSP22 proteins with B-Cry and
wtHSP27, while the interaction with HSP20 was not
affected.
Because of the possibility that mutations in HSP27
affect the HSP22/HSP27 interaction in a similar way,
we examined interaction properties of S135FHSP27, one
of the muHSP27 forms, which is associated with both
dHMN type II and CMT type 2F (14). The TH data
show that S135FHSP27 [23] or wtHSP27 [22] interact
similarly with wtHSP22 [13] (Fig. 7A). The negative TH
controls (C7, C13, C14) provided, as expected, negative
results (Fig. 5B, 7B). For the qFRET analysis, COS-7
cells were doubly transfected to express S135FHSP27-
CIT [25] or wtHSP27-CIT [24], together with wtHSP22-
CFP [5]. Representative cells with almost even cytoplas-
mic distribution of these fusion proteins are shown in
Fig. 7C. The AAFE values obtained for the interactions
of S135FHSP27 or wtHSP27 with wtHSP22 were signifi-
cantly different from the negative control, thus indicat-
ing interaction (Fig. 7D). The AAFE for the
S135FHSP27/wtHSP22 interaction was significantly
greater than for the wtHSP27/wtHSP22 interaction.
Thus, this muHSP27 form affects the HSP22/HSP27
interaction in a way similar to the two muHSP22 forms.
DISCUSSION
In the inherited disorders dHMN and CMT, the known
affected genes are involved in very different cellular
functions and pathways, including RNA processing and
metabolism (glycyl-tRNA synthetase, senataxin, immu-
noglobin -binding protein2), cytoskeletal functions
(dynactin, KIF1B, neurofilament L protein), and oth-
ers, thus illustrating the remarkable genetic heterogeneity
that underlies these diseases. An additional group of
affected genes is formed by the sHSPs (2–5). To date, it is
not clear how mutations in these seemingly unrelated
genes cause similar or even identical disease phenotypes.
Figure 5. TH assays of the interactions of
muHSP22 with other sHSPs. A) Assays to deter-
mine the interactions of K141EHSP22 [15] and
K141NHSP22 [17] with HSP20 [20], B-Cry [21],
and wtHSP27 [19]. The interactions with wtHSP22
[13] served as positive controls. B) Negative TH
controls: C7, C8, C9, pACT2 with wtHSP22 [13],
K141EHSP22 [15] or K141NHSP22 [17], respec-
tively; C10, C11, C12, pGBKT7 with HSP20 [20],
B-Cry [21], or HSP27 [19], respectively. Re-
porter gene designation and abbreviations are as
in Fig. 2.
Figure 6. qFRET measurements of the interactions of
muHSP22 with other sHSPs. A) Representative images of
doubly-transfected COS-7 cells without aggregates coexpress-
ing wtHSP22 [4], K141EHSP22 [6], or K141NHSP22 [8] with
HSP20 [10], B-Cry [11], or HSP27 [12] as CIT and CFP
fusion proteins as indicated. The bar indicates 50 m. B)
AAFE as determined by the qFRET method in doubly trans-
fected COS-7 cells. The measured interactions of wtHSP22,
K141EHSP22, or K141NHSP22 with the other sHSPs and the
constructs used were as in A. All sample values were signifi-
cantly different from the control. Significant differences
within each group (, muHSP22 vs. wtHSP22; , K141NHSP22
vs. K141EHSP22) are indicated. Abbreviations are as in Fig. 3.
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All of the currently eight known mutations in HSP22
and HSP27 are associated with the neuropathies dHMN
type II and CMT type 2 (6, 7, 14–16). In contrast, the
currently four known mutations in B-Cry, other than
those which affect exclusively the lens of the eye, are
associated with the myopathies desmin-related (myofi-
brillar) myopathy and dilated cardiomyopathy (17–19).
Thus, although B-Cry does interact with both HSP22
and HSP27 (11, 12, 30), mutations in this protein have
somewhat different pathological consequences. This
may indicate a different functional role for B-Cry, as
compared to HSP22 and HSP27, or alternatively, it
simply may reflect the high abundance of B-Cry in
heart and skeletal muscle tissues (31). Another remark-
able observation is that all these mutations have domi-
nant gain-of-function characteristics. The presence of
the wild-type proteins in the diseased tissues does not
prevent the manifestation of the diseases. A plausible
explanation is that the insertion of only a few mutated
protein molecules into heterooligomeric sHSP com-
plexes results in the formation of malstructured and
therefore malfunctioning sHSP complexes. Thus, the
model, based on aberrant sHSP-sHSP interactions may
provide the rationale for the genetic dominance, as is
seen in these diseases. In the case of the neuropathies,
the diseases show a late onset, indicating that the cell
damage, due to malfunctioning sHSP complexes, accu-
mulates over years before it becomes clinically manifest.
The data collected in this study show that both
disease-associated forms of muHSP22 interact with
wtHSP22, with themselves, and with the other sHSPs
HSP20, B-Cry and wtHSP27. Some of the interactions
involving muHSP22 exhibited increased stoichiometry,
while others remained unchanged. None of the inter-
actions was weakened. Each of the two muHSP22 forms
had a characteristic pattern of abnormal interactions. A
summary of the abnormal interactions as determined
for K141EHSP22 is given in Fig. 8A and that for
K141NHSP22 in Fig. 8B. The interaction characteristics
of K141NHSP22 deviated more from wtHSP22 than the
characteristics of K141EHSP22. Whether this correlates
to the clinical phenotype, e.g., the severity of the
associated diseases, remains to be determined.
We have investigated the interaction of one of the
HSP27 mutants (S135FHSP27) with HSP22 and found
increased interaction with wtHSP22. This suggests
that mutations in either HSP22 or HSP27 may result
in a similarly abnormal increase in the interaction
between both proteins (Fig. 8C) and that this in-
creased HSP22/HSP27 interaction then contributes
to the manifestation of both motor neuron diseases.
These data may reflect the existence of a relationship
between the three etiologic factors K141EHSP22,
K141NHSP22, and S135FHSP27 in one common pathway.
Although principally all proteins, depending on the
conditions, are prone to aggregate formation, mutant
proteins, in general, have a higher tendency to form
aggregates (32). Therefore, it is not surprising that
Figure 7. Interaction of S135FHSP27 with wtHSP22. A)
TH assay to determine the interaction of S135FHSP27
[23] with wtHSP22 [13]. The interaction of wtHSP27
[22] with wtHSP22 [13] served as positive control. B)
Negative TH controls: C7 (cf. Fig 5); C13, C14,
pGBKT7 with wtHSP27 [22] or S135FHSP27 [23],
respectively. C) Representative images of doubly trans-
fected COS-7 cells without aggregates co-expressing
S135FHSP27 [25] and wtHSP22 [5], or wtHSP27 [24]
and wtHSP22 [5] as CIT and CFP fusion proteins as
indicated. The bar indicates 50 m. D) AAFE as
determined by the qFRET method in doubly trans-
fected COS-7 cells. The measured interactions of
wtHSP27 and S135FHSP27 with wtHSP22 and the con-
structs used were as in C. Both sample values were
significantly different from the control. The signifi-
cant difference between the S135FHSP27/wtHSP22
interaction vs. the wtHSP27/wtHSP22 interaction is
indicated (). Reporter gene designation in A and B
is as in Fig. 2. Abbreviations: F, S135FHSP27; other
abbreviations are as in Fig. 3.
Fig. 8 Schematic of identified abnormal inter-
actions at the dimer level involving disease-
associated K141EHSP22, K141NHSP22, and
S135FHSP27. Single interactions were found un-
changed ( ), moderately increased ( ), or
greatly increased ( ) in comparison with the
corresponding wild-type sHSPs in the same interaction. A) K141EHSP22 has moderately increased interactions with itself, B-Cry,
and wtHSP27. B) K141NHSP22 has greatly increased interactions with itself, wtHSP22, and wtHSP27, and moderately increased
interaction with B-Cry. C) S135FHSP27 has moderately increased interaction with wtHSP22. Note that each muHSP22 form has
a characteristic, abnormal interaction pattern. That muHSP22 has increased interaction with wtHSP27 and that S135FHSP27 has
increased interaction with wtHSP22 and mutations in HSP22 or HSP27 resulting in a similar disease suggest that both mutant
proteins may act through the same mechanism.
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both mutant forms of HSP22 have an increased ten-
dency to form aggregates (Fig. 1E), similarly as was
reported previously (6). For three other sHSP mutants,
including P182LHSP27 (22), S135FHSP27 (14), and
R120GB-Cry (17, 23), this has been also demonstrated.
Although the R120GB-Cry aggregates meet the criteria
for true ameloid fibrils or aggresomes (23) usually seen
in neurodegenerative diseases, this characteristic re-
mains to be verified for the mutant HSP22 and HSP27
aggregates. Although protein aggregates frequently are
associated with disease, their significance for cell viabil-
ity is not clear. Aggregates may be cytotoxic, they may
be inert, or they even may be the end product of a
cellular “detoxifying” response (33). What seems clear
is that large mass end products of the aggregation
process are relatively benign as compared to the more
toxic early prefibrillar aggregates. Cytotoxicity for both
mutant forms of HSP22 in transfected neuronal cells
has been demonstrated previously (6). The fact that we
could not detect any cytotoxic effects of either mutant
form of HSP22 in COS-7 cells may have its cause in the
cell type used. More likely, however, is that 24 h after
transfection, the toxicity of the aggregates, be it in the
prefibrillar or in the fibrillar stage, has not yet devel-
oped, as it would several days after transfection. The
fact that no cytotoxic effects distort the data, as shown
in Fig. 1E, strengthens the conclusion that both mutant
forms of HSP22 have an increased tendency to form
aggregates as compared to wtHSP22. This increased ten-
dency of both muHSP22 proteins to form aggregates may
well be caused by their abnormally increased ability to
interact with wtHSP22 and with some of the other sHSPs.
In summary, the data presented here provide an
initial rationale for the pathogenesis of the muHSP22-
associated motor neuropathies dHMN and CMT. The
precise mechanism by which the aberrant interaction and
aggregate forming properties of muHSP22 translate into
the slow death of neurons remains to be elucidated.
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SPECIFIC AIMS
Mutations in the small heat shock protein HSP22,
K141EHSP22 and K141NHSP22, cause motor neuron de-
generation in the human diseases distal hereditary
motor neuropathy (dHMN) type II and Charcot-Marie-
Tooth disease (CMT) type 2L. Small heat shock pro-
teins (sHSP) interact with one another, and our aim
was to determine whether changes occurred in the inter-
action properties of both forms of mutant (mu) HSP22
with themselves, with wild-type (wt) HSP22, and with the
other sHSPs HSP27, HSP20, and B-crystallin (B-Cry),
all of which are abundant in neurons.
PRINCIPAL FINDINGS
1. Disease-associated muHSP22 has an increased
tendency to form intracellular protein aggregates
Mutant proteins, in general, have an increased ten-
dency to form cytoplasmic protein aggregates. Forma-
tion of aggregates involving muHSP22 may result from
aberrant interaction properties (see below), and it also
may interfere with the applied methods to determine
protein interactions. Therefore, the tendency of the
two known muHSP22 proteins to form aggregates was
examined in transfected COS-7 cells by determining
the proportion of cells containing protein aggregates.
In these assays, fusion proteins were used consisting of
the various sHSP species fused to derivatives of the
green fluorescent protein, citrine (CIT), or cyan fluo-
rescent protein (CFP). Twenty-four hours after trans-
fection, the proportion of cells containing aggregates
was quantified. Expression of K141EHSP22-CIT and
K141NHSP22-CIT resulted in a slight (21%) and great
(54%), respectively, increase in the proportion of
cells with aggregates, as compared to the wtHSP22-CIT
control (17%), which defines the baseline level for
this construct. Thus, both muHSP22 forms had, al-
though to a different extent, an increased tendency to
form aggregates as compared to wtHSP22.
Mutant proteins can recruit wild-type proteins into
aggregates, while wild-type proteins can attenuate aggre-
gate formation by mutant proteins. To evaluate this
mutual relationship, experiments were conducted in
which both muHSP22 forms and, for control also, wtHSP22
(all as CIT fusion proteins) were coexpressed with
wtHSP22, HSP20, B-Cry, and wtHSP27 (all as CFP fusion
proteins). Both muHSP22-CIT forms and also wtHSP22-
CIT were found to recruit all tested other sHSP-CFP
proteins (HSP20, B-Cry, wtHSP27, wtHSP22) into aggre-
gates. These wtsHSPs also significantly attenuated the
formation of aggregates by both muHSP22-CIT and
wtHSP22-CIT. However, the obtained patterns were differ-
ent for each tested sHSP. For example, aggregate forma-
tion by K141NHSP22-CIT was more effectively attenuated
by HSP20 and B-Cry than by wtHSP22 or wtHSP27, while
aggregate formation by wtHSP22-CIT was most effectively
attenuated by B-Cry and wtHSP27.
Collectively, these data indicate that both muHSP22
proteins have an increased tendency to form aggregates
and that aggregation can be attenuated by wtsHSPs. The
two muHSP22 proteins differ in their aggregate forma-
tion tendencies and in their responsiveness to attenua-
tion by wtHSP22 and other wtsHSPs, thus indicating
different properties of the two muHSP22 forms.
These data also demonstrate that in all settings
tested, a significant proportion of cells do not form
aggregates by 24 h after transfection. In these cells, the
sHSP-CIT/CFP fusion proteins show a relatively even
cytoplasmic distribution. Such cells were selected for
qFRET measurements, as described below.
2. Disease-associated muHSP22 shows abnormal
interaction with itself and with wtHSP22
We have determined the ability of the two known
muHSP22 forms to interact with themselves and with
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wtHSP22 using the yeast two-hybrid (TH) method. The
TH experiments indicated activation of the reporter
genes in all interactions tested (wtHSP22/wtHSP22;
K141EHSP22/wtHSP22; K141NHSP22/wtHSP22; K141EHSP22/
K141EHSP22; K141NHSP22/K141NHSP22). Thus, all HSP22
species interacted with one another. Within the limits of
this method, no differences in the interaction intensities
were observed as compared to the wtHSP22/wtHSP22
control interaction.
To determine differences in the binding stoichiom-
etry in these interactions, the more sensitive in vivo
quantitative fluorescence resonance energy transfer
(qFRET) method was applied. COS-7 cells were doubly
transfected with pairs (CIT, CFP) of the various forms
of HSP22 fusion protein cDNAs. The apparent average
fluorescence resonance energy transfer efficiency
(AAFE) values obtained for all tested interactions were
significantly different from the negative control, thus
indicating interaction (Fig. 1). The AAFE for the
K141EHSP22/wtHSP22 interaction was similar to that
of the wtHSP22/wtHSP22 interaction, while the AAFE
of the K141EHSP22/K141EHSP22 interaction was mod-
erately, though significantly, increased as compared
to the wtHSP22/wtHSP22 interaction. In contrast,
K141NHSP22 showed a strongly (approximately two-
fold) increased AAFE in the interactions with both
wtHSP22 and itself, as compared to wtHSP22.
Cross-linking was also used to determine homodimer
and oligomer formation of the various HSP22 species.
HEK-293T cells were transfected with vectors to express
myc-tagged wtHSP22, K141EHSP22, or K141NHSP22.
Forty-eight hours later, cells were treated with disuccin-
imidyl suberate, a homobifunctional cross-linker. The
analysis of the cross-linked proteins by SDS-PAGE/
Western blotting revealed that wtHSP22, K141EHSP22,
and K141NHSP22 form homodimers and possibly tet-
ramers. No major differences between wtHSP22 and
muHSP22 were observed.
Collectively, the TH, qFRET, and cross-linking data
suggest that the muHSP22 proteins interact with
wtHSP22 and themselves. Differences between the
muHSP22 forms and wtHSP22 could be demonstrated by
the qFRET method due to its greater sensitivity.
3. Disease-associated muHSP22 shows abnormal
interaction with other sHSPs
HSP22 is known to interact with HSP20, B-Cry, and
wtHSP27 that are known to be abundant in neuronal
cells. To determine potentially aberrant interaction
properties with these sHSPs, both muHSP22 forms were
probed in TH and qFRET assays. The TH data suggested
that both K141EHSP22 and K141NHSP22 interact with
HSP20, B-Cry, and wtHSP27. Within the limits of this
method, no differences in the interaction intensities be-
tween muHSP22 and wtHSP22 were observed.
The qFRET analysis in doubly transfected COS-7 cells
was performed as described above using CIT- and
CFP-sHSP fusion proteins. The AAFE values for both
K141EHSP22 and K141NHSP22 with HSP20 as interacting
partner were not significantly different from that of
wtHSP22, suggesting that the mutations do not affect
this interaction (Fig. 2, HSP20 group). In contrast, the
Figure 1. qFRET measurements of the interactions of
K141EHSP22 and K141NHSP22 with wtHSP22 and with them-
selves in doubly transfected COS-7 cells 24 h after transfec-
tion. The AAFE was determined in cells expressing the
various HSP22 species as indicated. The HSP22 species were
used as CIT (top row of the abscissa legend) and CFP fusion
proteins (bottom row of the abscissa legend). All sample
values were significantly different from the negative control
(expression of CIT and CFP). Significant differences from the
wtHSP22/wtHSP22 (positive control) interaction (), from the
wtHSP22/K141EHSP22 interaction (), and from the
K141EHSP22/K141EHSP22 interaction () are indicated where
appropriate. Abbreviations: C, control; wt, wtHSP22; E,
K141EHSP22; N, K141NHSP22.
Figure 2. qFRET measurements of the interactions of
K141EHSP22, K141NHSP22, and wtHSP22 (positive control)
with HSP20, B-Cry, and wtHSP27 in doubly transfected
COS-7 cells 24 h after transfection. The AAFE was determined
in cells coexpressing wtHSP22-CIT (open columns),
K141EHSP22-CIT (gray columns), or K141NHSP22-CIT (solid
columns) with HSP20-CFP, B-Cry-CFP, and wtHSP27-CFP.
All sample values were significantly different from the nega-
tive control (expression of CIT and CFP). Significant differ-
ences within each group (, muHSP22 vs. wtHSP22; ,
K141NHSP22 vs. K141EHSP22) are indicated. Abbreviations are
as in Fig. 1.
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AAFE values for both K141EHSP22 and K141NHSP22 with
B-Cry as interacting partner were moderately, al-
though significantly, increased (B-Cry group) as com-
pared with wtHSP22, suggesting that this interaction is
affected by both mutations. The AAFE values for both
muHSP22 proteins were similar when compared to each
other. Finally, the AAFE values for K141EHSP22 and
K141NHSP22 were moderately and strongly increased,
respectively, with HSP27 as interacting partner (HSP27
group), as compared with wtHSP22. Thus, both muta-
tions result in increased interaction with HSP27, al-
though to a different extent.
4. Disease-associated S135FHSP27 shows abnormal
interaction with wtHSP22
dHMN and CMT are clinically and genetically hetero-
geneous groups of neuropathies. In addition to muta-
tions in HSP22, several mutations in HSP27 (muHSP27)
have been identified that are also associated with
dHMN and CMT. Because muHSP27 may affect the
HSP22/HSP27 interaction in a manner similar to
muHSP22, one of the known muHSP27 forms
(S135FHSP27) was also included in these experiments.
The TH data showed that S135FHSP27 interacts with
wtHSP22, in a manner similar to wtHSP27.
For the qFRET analysis, COS-7 cells were doubly
transfected to express S135FHSP27-CIT or wtHSP27-CIT
(positive control), together with wtHSP22-CFP. The
AAFE values obtained for the interactions of
S135FHSP27 and wtHSP27 with wtHSP22 were signifi-
cantly different from the negative control, thus indicat-
ing interaction. The AAFE for the S135FHSP27/wtHSP22
interaction was significantly greater than for the
wtHSP27/wtHSP22 interaction. Thus, this muHSP27
form affects the HSP22/HSP27 interaction in a similar
way as the two studied muHSP22 forms do.
CONCLUSION AND SIGNIFICANCE
This work shows that both disease-associated forms of
muHSP22 interacted with wtHSP22, with themselves,
and with the other sHSPs HSP20, B-Cry, and HSP27.
The stoichiometry of some of the analyzed interactions
was increased, while others remained unchanged.
None of the interactions was weakened. Each of the two
muHSP22 forms had a characteristic pattern of aber-
rant interactions. The interaction characteristics of
K141NHSP22 deviated more from wtHSP22 than those of
K141EHSP22. Whether this correlates to the clinical
phenotype, e.g., the severity of the associated diseases,
remains to be determined. The aberrant interactions of
muHSP22 proteins may relate to their increased ability
to form aggregates. The more aberrant interaction
properties of K141NHSP22 may explain the greatly in-
creased formation of aggregates. One of the dHMN-
and CMT-associated HSP27 mutants (S135FHSP27)
was also found to have an abnormally increased
interaction with wtHSP22. A summary of the identified
abnormal interactions of K141EHSP22, K141NHSP22, and
S135FHSP27 is given in Fig. 3A, B, and C, respectively.
The facts that HSP22 and HSP27 are interacting
proteins and that either muHSP22 or muHSP27 result in
similarly increased interaction between both proteins,
support the hypothesis that mutations in either protein
affect the same pathway or protein complex. All known
mutations in HSP22 and HSP27 have dominant gain-
of-function characteristics, and the presence of the
wtsHSPs in the diseased tissues cannot prevent the
development of the diseases. A plausible explanation is
that insertion of only a few mutated protein molecules
into the sHSP complexes may result in the formation of
malstructured and thus malfunctioning complexes.
Thus, the model based on aberrant sHSP interactions
may provide the rationale for the genetic dominance as
is seen in these diseases.
In summary, the data presented here may provide
the rationale for the pathogenesis of the mutant sHSP-
associated motor neuropathies dHMN and CMT. The
molecular and cellular events by which the abnor-
mal interactions and aggregate-forming properties of
muHSP22 translate finally into the slow death of motor
neurons remain to be elucidated.
Figure 3. Schematic of identified abnormal
interactions at the dimer level involving disease-
associated K141EHSP22, K141NHSP22, and
S135FHSP27. Single interactions were found un-
changed ( ), moderately increased ( ), or
greatly increased ( ) in comparison with the
corresponding wild-type sHSPs in the same interaction. A) K141EHSP22 has moderately increased interactions with itself, B-Cry,
and wtHSP27. B) K141NHSP22 has greatly increased interactions with itself, wtHSP22, and wtHSP27, and moderately increased
interaction with B-Cry. C) S135FHSP27 has moderately increased interaction with wtHSP22. Note that each muHSP22 form has
a characteristic, abnormal interaction pattern. That muHSP22 has increased interaction with wtHSP27 and that S135FHSP27 has
increased interaction with wtHSP22 and mutations in HSP22 or HSP27 resulting in a similar disease suggest that both mutant
proteins may act through the same mechanism.
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